Trial Profile
BARCOVID19 Study:Phase I Clinical Trial to Evaluate the Safety of Baricitinib to Prevent Respiratory Insufficiency Progression in Oncohematological Patients Affected with COVID-19
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Corticosteroids; Dexamethasone; Remdesivir; Tocilizumab
- Indications COVID 2019 infections; Respiratory insufficiency
- Focus Adverse reactions
- Acronyms BARCOVID19 Study
- 27 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition